SOUTH SAN FRANCISCO, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Exelixis, Inc. today announced the closing of its public offering of 11.5 million shares of common stock, including 1.5 million shares issued upon exercise of an option granted to the underwriters to cover over-allotments, at a public offering price of $8.40 per share. The aggregate net proceeds of the offering, after payment of underwriting discounts and estimated offering expenses, are $90.5 million.
Goldman, Sachs & Co. acted as the sole book-running manager for the offering. Cowen and Company, LLC acted as the joint lead manager for the offering, and Banc of America Securities LLC and Piper Jaffray & Co. acted as co-managers for the offering.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About Exelixis
Exelixis, Inc. is a biotechnology company dedicated to the discovery and development of novel therapeutics that will potentially enhance the care and lives of patients with cancer and other serious diseases.
Exelixis, Inc.
CONTACT: Frank Karbe, Chief Financial Officer, +1-650-837-7565, orfkarbe@exelixis.com, or Charles Butler, Director, Corporate Communications,+1-650-837-7277, or cbutler@exelixis.com, both of Exelixis, Inc.
Web site: http://www.exelixis.com/
